CMN Weekly (3 December 2021) - Your Weekly CRISPR...
Dec. 3, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Spotlight Therapeutics
Main focus: In vivo gene therapies
Company stage: Pre-clinical
Diseases: Ocular diseases, haemoglobinopathies and immunooncology
Genome editing tool: CRISPR (undisclosed type)
Funding stage: Private
Location: San Francisco Bay Area, CA, USA
Website: https://www.spotlighttx.com/
Spotlight Therapeutics is an early stage pre-clinical gene-editing company. Spotlight is focused on developing first-in-class in vivo gene-editing therapeutics. To do this it uses its proprietary technology platform Targeted Active Gene Editors (TAGE). The TAGE platform allows the company to address both delivery and in vivo CRISPR editing shortcomings.
